国产91亚洲福利精品一区二区,国产综合成人久久大片91,国产成人精品久久综合,久久久91精品国产一区二区三区,91福利国产在线在线播放,91精品国产高清久久久久久91,91精品国产福利在线观看麻豆,国产免费一区二区三区在线观看

熱門(mén)搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購(gòu)物車(chē) 1 種商品 - 共0元
當(dāng)前位置: 首頁(yè) > ATCC代理 > LS132.1D9 [1D9]
▍最近瀏覽歷史
▍更多產(chǎn)品
▍聯(lián)系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號(hào)
  • 創(chuàng)e慧谷42號(hào)樓B幢401室
LS132.1D9 [1D9]
LS132.1D9 [1D9]
規(guī)格:
貨期:
編號(hào):B209801
品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株
定量菌液
DNA
RNA

規(guī)格:
凍干粉
斜面
甘油
平板


產(chǎn)品名稱(chēng) LS132.1D9 [1D9]
商品貨號(hào) B209801
Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:
Product Format frozen
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease Lymphoma
Strain

Strain:? C57BL/6? (B cell); BALB/c? (myeloma)
Applications
The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region.
Storage Conditions liquid nitrogen vapor phase
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Comments
Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2).
Complete Growth Medium Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 25 mM HEPES, 20 pg/ml mouse recombinant Interleukin-6 (IL-6) and 20% fetal bovine serum
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml.
Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgG2a kappa
Name of Depositor LeukoSite, Inc.
U.S. Patent Number
References

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001

LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002

LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002

LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002

LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002

LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002

. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002

LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002

梅經(jīng)理 17280875617 1438578920
胡經(jīng)理 13345964880 2438244627
周經(jīng)理 17757487661 1296385441
于經(jīng)理 18067160830 2088210172
沈經(jīng)理 19548299266 2662369050
李經(jīng)理 13626845108 972239479
茂名市| 社会| 靖江市| 乐陵市| 和田县| 银川市| 江都市| 大连市| 永春县| 乌鲁木齐市| 漠河县| 安丘市| 增城市| 霍邱县| 彰化县| 禹州市| 江北区| 龙井市| 哈尔滨市| 合川市| 东源县| 丰台区| 奉新县| 郁南县| 当雄县| 奇台县| 大连市| 肥西县| 和田县| 洪江市| 浙江省| 含山县| 黄石市| 鹤壁市| 巴东县| 翁源县| 梨树县| 元氏县| 包头市| 堆龙德庆县| 钦州市|